CA2666974A1 - Fully human anti-vegf antibodies and methods of using - Google Patents

Fully human anti-vegf antibodies and methods of using Download PDF

Info

Publication number
CA2666974A1
CA2666974A1 CA002666974A CA2666974A CA2666974A1 CA 2666974 A1 CA2666974 A1 CA 2666974A1 CA 002666974 A CA002666974 A CA 002666974A CA 2666974 A CA2666974 A CA 2666974A CA 2666974 A1 CA2666974 A1 CA 2666974A1
Authority
CA
Canada
Prior art keywords
antibody
seq
xpa
vegf
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666974A
Other languages
English (en)
French (fr)
Inventor
Sumant Ramachandra
Walter Robert Bishop
Linda Masat
Chao Bai Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Technology Ltd
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666974A1 publication Critical patent/CA2666974A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002666974A 2006-10-20 2007-10-22 Fully human anti-vegf antibodies and methods of using Abandoned CA2666974A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85326006P 2006-10-20 2006-10-20
US60/853,260 2006-10-20
PCT/US2007/082164 WO2008133706A2 (en) 2006-10-20 2007-10-22 Fully human anti-vegf antibodies and methods of using

Publications (1)

Publication Number Publication Date
CA2666974A1 true CA2666974A1 (en) 2008-11-06

Family

ID=39926241

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666974A Abandoned CA2666974A1 (en) 2006-10-20 2007-10-22 Fully human anti-vegf antibodies and methods of using

Country Status (7)

Country Link
US (1) US20110076279A1 (OSRAM)
EP (1) EP2086583A4 (OSRAM)
JP (1) JP2010507594A (OSRAM)
CN (1) CN102006885A (OSRAM)
CA (1) CA2666974A1 (OSRAM)
MX (1) MX2009004027A (OSRAM)
WO (1) WO2008133706A2 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
KR101093717B1 (ko) * 2008-11-26 2011-12-19 한국생명공학연구원 Ｖｅｇｆ―특이적인 인간항체
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
PL2488204T3 (pl) 2009-10-16 2016-10-31 Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych
CN102167740B (zh) * 2010-02-25 2014-06-04 上海百迈博制药有限公司 一种全人源抗vegf单克隆抗体、其制备方法及用途
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN102757495A (zh) * 2011-04-26 2012-10-31 中国人民解放军第二军医大学 一种全人源抗vegf抗体、其制备方法及用途
CN102875676B (zh) * 2011-07-13 2014-11-05 无锡天演生物技术有限公司 全人源抗人vegf单抗分子及其应用
DK3485903T5 (da) 2011-09-23 2024-09-02 Mereo Biopharma 5 Inc Vegf/dll4-bindende midler og anvendelser deraf
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
WO2014104406A1 (ja) * 2012-12-27 2014-07-03 学校法人慶應義塾 骨粗鬆症治療剤及び治療剤のスクリーニング方法
KR20150132581A (ko) * 2013-12-31 2015-11-25 재단법인 생물기술개발중심 항-vegf 항체 및 그것의 용도
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6827415B2 (ja) 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
US10640772B2 (en) 2015-11-30 2020-05-05 Nissan Chemical Industries, Ltd. DNA aptamers binding to molecular targeted agents and detection method of molecular targeted medicine using the same
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CA3034576A1 (en) 2016-08-23 2018-03-01 Medimmune Limited Anti-vegf-a antibodies and uses thereof
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN113272323A (zh) * 2018-12-21 2021-08-17 豪夫迈·罗氏有限公司 用于改善抗vegf抗体对vegf与vegf-r1的结合的抑制的方法
WO2021013064A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 一种人源化vegfr2抗体及其应用
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN116265015A (zh) * 2021-12-16 2023-06-20 石药集团中奇制药技术（石家庄）有限公司 多西他赛白蛋白组合物与vegf抑制剂或vegfr抑制剂的组合及其用途
CN118974097A (zh) * 2022-03-30 2024-11-15 西安奥瑞单抗生物技术有限公司 抗psma抗体、其变体及其用途
CN115850470B (zh) * 2022-12-12 2023-07-07 三门峡市眼科医院 Vegf抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045331A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
ES2405944T3 (es) * 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
CN102936284A (zh) * 2005-02-02 2013-02-20 马萨诸塞州大学 人抗狂犬病抗体及其用途
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using

Also Published As

Publication number Publication date
WO2008133706A8 (en) 2010-05-14
WO2008133706A2 (en) 2008-11-06
CN102006885A (zh) 2011-04-06
EP2086583A2 (en) 2009-08-12
EP2086583A4 (en) 2010-05-26
WO2008133706A3 (en) 2009-02-19
JP2010507594A (ja) 2010-03-11
US20110076279A1 (en) 2011-03-31
MX2009004027A (es) 2009-09-28

Similar Documents

Publication Publication Date Title
US20110076279A1 (en) Fully human anti-vegf antibodies and methods of using
US8143025B2 (en) Antibodies against vascular endothelial growth factor receptor-1
US8216571B2 (en) Fully human anti-VEGF antibodies and methods of using
JP5769969B2 (ja) Ａｘｌ抗体
ES2527871T3 (es) Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
US20090022714A1 (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
KR20040023590A (ko) 혈관 내피 성장 인자 수용체 길항제를 이용한 종양 성장의병용 억제 방법
JP2011505120A5 (OSRAM)
US20090246205A1 (en) Inhibition of macrophage-stimulating protein receptor (ron)
US20150110788A1 (en) Bispecific antibodies with an fgf2 binding domain
US20210238297A1 (en) Highly potent antibodies binding to death receptor 4 and death receptor 5
KR20220151684A (ko) 암의 치료 및/또는 예방을 위한 의약품
US20150152193A1 (en) Axl antibodies
TW202543685A (zh) 抗體藥物偶聯物及其製備方法和用途
EA036257B1 (ru) Антитела человека против vegfr-2/kdr
HK1115302B (en) Antibodies against vascular endothelial growth factor receptor-1

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20131022